Ruth L. Coleman - Concepedia

Author

Ruth L. Coleman

Oxford Centre for Diabetes, Endocrinology and Metabolism ORCID

Also Known As

Coleman, R, Coleman, Ruth, R Coleman, R L Coleman, R. Coleman, R. L. Coleman, R.L. Coleman, RUTH L. COLEMAN, Roger Tavendale, Rury Holman

131

Publications

3.7K

Citations

H-Index

Concepts

All Affiliations

Oxford Centre for Diabetes, Endocrinology and Metabolism University of Oxford Churchill Hospital John Radcliffe Hospital Oxford BioMedica (United Kingdom)

About

Ruth L. Coleman is an author at Oxford Centre for Diabetes, Endocrinology and Metabolism specializing in diabetes, medicine, and metabolic syndrome.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	713
2	Diabetes	6	6	713
3	Public Health	5	5	675
4	Epidemiology	3	3	311
5	Cell Biology	1	1	48

Ruth L. Coleman

Publications

2.3K

Citations

H-Index

Page 1

	Year	Citations
Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial Rury R. Holman, Ruth L. Coleman, Juliana C.N. Chan, The Lancet Diabetes & Endocrinology Metabolic SyndromeGlucose ToleranceDiabetes ManagementCardiovascular DiseaseHealth Policy	2017	316
Risk Factors for Myocardial Infarction Case Fatality and Stroke Case Fatality in Type 2 Diabetes Richard Stevens, Ruth L. Coleman, Amanda Adler, Diabetes Care	2004	295
'Computer modeling of diabetes and its complications: A report on the Fourth Mount Hood Challenge Meeting' Andrew Palmer, S Roze, Valentine Wn, eCite Digital Repository (University of Tasmania)	2007	199
Framingham, SCORE, and DECODE Risk Equations Do Not Provide Reliable Cardiovascular Risk Estimates in Type 2 Diabetes Ruth L. Coleman, Richard Stevens, Ravi Retnakaran, Diabetes Care Cardiometabolic RiskPreventive CardiologyCoronary Artery DiseaseMetabolic SyndromeDiabetes Epidemiology	2007	182
Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC- Norfolk Cohort Rebecca K. Simmons, Ruth L. Coleman, Hermione Price, Diabetes Care	2008	147
Historical HbA1c Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88 Marcus Lind, Henrik Imberg, Ruth L. Coleman, Diabetes Care	2021	117
Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91) Amanda Adler, Ruth L. Coleman, José Leal, The Lancet	2024	117
Prognostic Significance of Silent Myocardial Infarction in Newly Diagnosed Type 2 Diabetes Mellitus Timothy M. E. Davis, Ruth L. Coleman, Rury R. Holman Circulation	2013	115
Assessment of Cardiac Energy Metabolism, Function, and Physiology in Patients With Heart Failure Taking Empagliflozin: The Randomized, Controlled EMPA-VISION Trial Moritz Hundertmark, Amanda Adler, Charalambos Antoniades, Circulation	2023	95
Ethnicity and long‐term vascular outcomes in Type 2 diabetes: a prospective observational study (UKPDS 83) Timothy M. E. Davis, Ruth L. Coleman, Rury R. Holman Diabetic Medicine	2013	69

Page 1